• Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scope

• Adjusted recurring operating income² of 18.3% as a ratio to revenue, in line with our expectations

  • Down compared to 2024 due to phasing and non-recurring effects

• 2025 targets confirmed

  • Revenue growth expected between 4% and 6% at constant rates and scope

  • Adjusted recurring operating income¹ expected around 16%

Our team, responsible for drug registration and maintaining and defending Marketing Authorizations (MAs), is ready to reveal what they do.

In the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation